Advertisement


Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

2019 Genitourinary Cancers Symposium

Advertisement

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses current models used to estimate the risk of recurrence as well as genomic data that could help pinpoint individual tumor biology.



Related Videos

Bladder Cancer

Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?

Jason A. Efstathiou, MD, DPhil, of Massachusetts General Hospital, discusses the debate over treating muscle-invasive bladder cancer with radical cystectomy vs trimodality therapy.

Prostate Cancer

Howard I. Scher, MD, on Prostate Cancer: Circulating Tumor Cells as a Surrogate Endpoint for Survival

Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials on metastatic castration-resistant prostate cancer (Abstract 143).

Prostate Cancer

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Nicholas J. van As, MD, of The Royal Marsden NHS Foundation Trust, discusses an analysis of acute toxicity in the PACE-B study, which compared stereotactic body radiotherapy with conventionally fractionated or moderately hypofractionated external-beam radiotherapy for localized prostate cancer (Abstract 1).

Kidney Cancer
Immunotherapy

Brian I. Rini, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Results From the KEYNOTE-426 Trial on Pembrolizumab Plus Axitinib vs Sunitinib

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and Thomas Powles, MD, PhD, of Queen Mary University of London, discuss their study findings on pembrolizumab plus axitinib vs sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (Abstract 543).

Bladder Cancer

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel

Thomas Powles, MD, PhD, of Queen Mary University of London, discusses phase III study findings on ramucirumab plus docetaxel vs placebo plus docetaxel in patients with advanced platinum-refractory urothelial carcinoma (Abstract 353).

Advertisement

Advertisement




Advertisement